Alliance Global raised the firm’s price target on vTv Therapeutics (VTVT) to $55 from $35 and keeps a Buy rating on the shares. The company’s Q4 report highlighted the ongoing progression of its Phase 3 clinical trial of cadisegliatin in type 1 diabetes, the analyst tells investors in a research note. Alliance values cadisegliatin for type 1 diabetes in the U.S. at $33 per share.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- Buy Rating on vTv Therapeutics Underpinned by Late-Stage T1D Catalyst, Strengthened Balance Sheet, and Diversified Partnership-Driven Upside
- vTv Therapeutics Highlights Cadisegliatin Phase 3 and Cash Runway
- vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09)
- vTv Therapeutics Highlights Cadisegliatin Progress and Financial Strength
- vTv Therapeutics Inc. (VTVT) Q4 Earnings Cheat Sheet